Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 169-179

  Kuger, Sebastian ^a   Graus, Dorothea ^a   Brendtke, Rico ^a   Günther, Nadine ^a   Katzer, Astrid ^a   Lutyj, Paul ^a   Polat, Bülent ^a   Chatterjee, Manik ^a   Sukhorukov, Vladimir L ^a   Flentje, Michael ^a   Djuzenova, Cholpon S ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; HISTONE H2AX; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; FLOW CYTOMETRY; GIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; RADIATION DOSE; RADIOSENSITIZATION; WESTERN BLOTTING;

EID: 84875762286     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12364     Document Type: Article

References (48)

1. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, et al. (1978). Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49, 333-343.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
3. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, and Tsukada Y (1983). Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52, 997-1007.
4. Hofer S and Herrmann R (2001). Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J Cancer Res Clin Oncol 127, 91-95.
5. Fan Q-W and Weiss WA (2010). Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347, 279-296.
6. El-Deiry WS (2003). The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22, 7486-7495.
7. Nicholson KM and Anderson NG (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14, 381-395.
8. Nakashio A, Fujita N, Rokudai S, Sato S, and Tsuruo T (2000). Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecaninduced apoptosis. Cancer Res 60, 5303-5309.
9. Janmaat ML, Kruyt FA, Rodriguez JA, and Giaccone G (2003). Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9, 2316-2326.
10. Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
11. Bjornsti MA and Houghton PJ (2004). The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4, 335-348.
12. Xia S, Zhao Y, Yu S, and Zhang M (2010). Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm 25, 317-323.
13. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, and Jendrossek V (2010). The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 5, 108.
14. Zhang T, Cui GB, Zhang J, Zhang F, Zhou YA, Jiang T, and Li XF (2010). Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep 24, 1683-1689.
15. Kao GD, Jiang Z, Fernandes AM, Gupta AK, and Maity A (2007). Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282, 21206-21212.
16. Li H-F, Kim J-S, and Waldman T (2009). Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4, 43.
17. Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzalez-Suarez I, Wang S, Zhang J, Roti Roti JL, Gonzalo S, and Zhang J (2011). The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res 175, 214-224.
18. Gottschalk AR, Doan A, Nakamura JL, Stokoe D, and Haas-Kogan DA (2005). Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 63, 1221-1227.
19. Manning BD (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167, 399-403.
20. Markman B, Dienstmann R, and Tabernero J (2010). Targeting the PI3K/Akt/ mTOR pathway-beyond rapalogs. Oncotarget 1, 530-543.
21. Wan X, Harkavy B, Shen N, Grohar P, and Helman LJ (2006). Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940.
22. Stein RC (2001). Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8, 237-248.
23. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, and McKenna WG (2003). Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56, 846-853.
24. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7, 1851-1863.
25. Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, et al. (2012). The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgEdependent activation of human mast cells and basophils. PLoS One 7, e29925.
26. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, and Mier JW (2010). The efficacy of the novel dual PI3-kinase/ mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16, 3628-3638.
27. KongD and Yamori T (2008). Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 99, 1734-1740.
28. Xu CX, Li Y, Yue P, Owonikoko TK, Ramalingam SS, Khuri FR, and Sun SY (2011). The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 6, e20899.
29. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, and Scaglioni PP (2009). Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69, 7644-7652.
30. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, et al. (2012). Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72, 239-248.
31. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, and Muschel RJ (2012). NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol 7, 48.
32. Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, and Burma S (2012). The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses. Neoplasia 14, 34-43.
33. Azad A, Jackson S, Cullinane C, Natoli A, Neilsen PM, Callen DF, Maira SM, Hackl W, McArthur GA, and Solomon B (2011). Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res 9, 1696-1707.
34. Djuzenova C, Mühl B, Schakowski R, Oppitz U, and Flentje M (2004). Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients. Br J Cancer 90, 2356-2363.
35. Muslimovic A, Ismail IH, Gao Y, and Hammarsten O (2008). An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells. Nat Protoc 3, 1187-1193.
36. Djuzenova CS, Sukhorukov VL, Klöck G, Arnold WM, and Zimmermann U (1994). Effect of electric field pulses on the viability and on the membranebound immunoglobulins of LPS-activated murine B-lymphocytes: correlation with the cell cycle. Cytometry 15, 35-45.
37. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, et al. (2010). NVPBEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16, 530-540.
38. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, and Blenis J (2004). mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24, 200-216.
39. Foster DA, Yellen P, Xu L, and Saqcena M (2010). Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer 1, 1124-1131.
40. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998). DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273, 5858-5868.
41. Nyati MK, Morgan MA, Feng FY, and Lawrence TS (2006). Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6, 876-885.
42. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, and Nyati MK (2006). Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66, 981-988.
43. Gulati N, Karsy M, Albert L, Murali R, and Jhanwar-Uniyal M (2009). Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol 35, 731-740.
44. Julien L-A, Carriere A, Moreau J, and Roux PP (2010). mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30, 908-921.
45. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, and Rosen N (2011). mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1, 248-259.
46. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, et al. (2010). Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 70, 8097-8107.
47. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, and Yung WK (2009). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8, 2204-2210.
48. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira SM, et al. (2009). Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7, 601-613.